The objective of the current study was to evaluate the effectiveness and safety of conversion to oral tapentadol ER ( 50-250 mg twice daily ) from previous around-the-clock strong opioid therapy in patients with moderate to severe , chronic malignant tumor-related cancer pain that was well-controlled .